CARUSO JAMES V 4
4 · Cellectar Biosciences, Inc. · Filed Mar 5, 2021
Insider Transaction Report
Form 4
CARUSO JAMES V
DirectorPresident and CEO
Transactions
- Purchase
Common Stock
2021-03-04$1.70/sh+5,100$8,659→ 86,401 total - Award
Stock option (right to buy)
2021-03-04+1,600,000→ 1,600,000 totalExercise: $1.74Exp: 2031-03-04→ Common Stock (1,600,000 underlying) - Sale
Series A Warrants
2021-03-04$0.19/sh+46,948$8,718→ 0 totalExercise: $30.40From: 2016-04-20Exp: 2021-04-20→ Common Stock (4,694 underlying)
Footnotes (3)
- [F1]Mr. Caruso used the proceeds of the sale of the Series A Warrants, which expire in April 2021, to purchase shares of Cellectar's common stock.
- [F2]Ten warrants are convertible into one share of Cellectar's common stock at an exercise price of $30.40 per share of common stock.
- [F3]This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of shares available under Cellectar's equity incentive plans at Cellectar's 2021 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.